Processing of CFTR: Traversing the cellular maze - How much CFTR needs to go through to avoid cystic fibrosis?

被引:77
作者
Amaral, MD
机构
[1] Univ Lisbon, Fac Sci, Dept Chem & Biochem, P-1749016 Lisbon, Portugal
[2] Natl Inst Hlth Dr Ricardo Jorge, Ctr Human Genet, Lisbon, Portugal
关键词
cystic fibrosis transmembrane conductance regulator; CFTR-interacting proteins; endoplasmic reticulum; processing; maturation; traffic; F508del;
D O I
10.1002/ppul.20168
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Biosynthesis of the cystic fibrosis transmembrane conductance regulator (CFTR), like other proteins aimed at the cell surface, involves transport through a series of membranous compartments, the first of which is the endoplasmic reticulum (ER), where CFTR encounters the appropriate environment for folding, oligomerization, maturation, and export from the ER. After exiting the ER, CFTR has to traffic through complex pathways until it reaches the cell surface. Although not yet fully understood, the fine details of these pathways are starting to emerge, partially through identification of an increasing number of CFTR-interacting proteins (CIPs) and the clarification of their roles in CFTR trafficking and function. These aspects of CFTR biogenesis/degradation and by membrane traffic and CIPs are discussed in this review. Following this description of complex pathways and multiple checkpoints to which CFTR is subjected in the cell, the basic question remains of how much CFTR has to overcome these barriers and be functionally expressed at the plasma membrane to avoid CF. This question is also discussed here.
引用
收藏
页码:479 / 491
页数:13
相关论文
共 109 条
  • [1] The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator
    Alberti, S
    Böhse, K
    Arndt, V
    Schmitz, A
    Höhfeld, J
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (09) : 4003 - 4010
  • [2] CFTR and chaperones - Processing and degradation
    Amaral, MD
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2004, 23 (1-2) : 41 - 48
  • [3] Cystic fibrosis patients with the 3272-26A>G splicing mutation have milder disease than F508del homozygotes:: a large European study
    Amaral, MD
    Pacheco, P
    Beck, S
    Farinha, CM
    Penque, D
    Nogueira, P
    Barreto, C
    Lopes, B
    Casals, T
    Dapena, J
    Gartner, S
    Vásquez, C
    Pérez-Frías, J
    Olveira, C
    Cabanas, R
    Estivill, X
    Tzetis, M
    Kanavakis, E
    Doudounakis, S
    Dörk, T
    Tümmler, B
    Girodon-Boulandet, E
    Cazeneuve, C
    Goossens, M
    Blayau, M
    Verlingue, C
    Vieira, I
    Féréc, C
    Claustres, M
    des Georges, M
    Clavel, C
    Birembaut, P
    Hubert, D
    Bienvenu, T
    Adoun, M
    Chomel, JC
    De Boeck, K
    Cuppens, H
    Lavinha, J
    [J]. JOURNAL OF MEDICAL GENETICS, 2001, 38 (11) : 777 - 782
  • [4] Beck S, 1999, HUM MUTAT, V14, P133, DOI 10.1002/(SICI)1098-1004(1999)14:2<133::AID-HUMU5>3.3.CO
  • [5] 2-K
  • [6] COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from post-Golgi compartments
    Benharouga, M
    Haardt, M
    Kartner, N
    Lukacs, GL
    [J]. JOURNAL OF CELL BIOLOGY, 2001, 153 (05) : 957 - 970
  • [7] Syntaxin 8 impairs trafficking of cystic fibrosis transmembrane conductance regulator (CFTR) and inhibits its channel activity
    Bilan, F
    Thoreau, V
    Nacfer, M
    Dérand, R
    Norez, C
    Cantereau, A
    Garcia, M
    Becq, F
    Kitzis, A
    [J]. JOURNAL OF CELL SCIENCE, 2004, 117 (10) : 1923 - 1935
  • [8] CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds
    Caci, E
    Folli, C
    Zegarra-Moran, O
    Ma, TH
    Springsteel, MF
    Sammelson, RE
    Nantz, MH
    Kurth, MJ
    Verkman, AS
    Galietta, LJV
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2003, 285 (01) : L180 - L188
  • [9] Removal of multiple arginine-framed trafficking signals overcomes misprocessing of ΔF508 CFTR present in most patients with cystic fibrosis
    Chang, XB
    Cui, LY
    Hou, YX
    Jensen, TJ
    Aleksandrov, AA
    Mengos, A
    Riordan, JR
    [J]. MOLECULAR CELL, 1999, 4 (01) : 137 - 142
  • [10] Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL
    Cheng, J
    Wang, H
    Guggino, WB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (03) : 1892 - 1898